This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Steele, J.
Right arrow Articles by Woodman, C. B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steele, J.
Right arrow Articles by Woodman, C. B. J.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, September 2008, p. 1387-1390, Vol. 15, No. 9
1071-412X/08/$08.00+0     doi:10.1128/CVI.00013-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Measurement of the Humoral Immune Response following an Incident Human Papillomavirus Type 16 or 18 Infection in Young Women by a Pseudovirion-Based Neutralizing Antibody Assay{triangledown}

Jane Steele,1*,{dagger} Stuart Collins,2,{dagger} Kaisheng Wen,1 Gordon Ryan,1 Christothea Constandinou-Williams,1 and Ciaran B. J. Woodman1

CRUK Institute for Cancer Studies,1 CRUK Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom2

Received 4 January 2008/ Returned for modification 8 May 2008/ Accepted 2 July 2008

We have evaluated a neutralizing antibody assay which uses human papillomavirus (HPV) type 16 (HPV-16) and HPV-18 pseudovirions carrying a secretory alkaline phosphatase reporter gene and which can potentially measure functionally relevant HPV type-specific neutralizing antibodies. The reproducibility of the assay was excellent; for HPV-16, the intra- and interassay kappa values were 0.95 and 0.90, respectively; and for HPV-18, the corresponding values were 0.90 and 0.90. This assay was used to describe the kinetics of the neutralizing antibody response in a cohort of 42 young women who were recruited soon after first intercourse and who first tested positive for HPV-16 DNA or HPV-18 DNA, or both, during follow-up. Most women seroconverted following the first detection of type-specific HPV DNA and remained seropositive until the end of follow-up. Our findings are broadly consistent with those of two other cohort studies which have measured the serological response following an incident infection by using the technically simpler virus-like-particle-based enzyme-linked immunosorbent assay.

* Corresponding author. Mailing address: CRUK Institute for Cancer Studies, University of Birmingham, Vincent Drive, Edgbaston, Birmingham B15 2TT, United Kingdom. Phone: 0121 414 7458. Fax: 0121 414 4486. E-mail: j.c.steele{at}bham.ac.uk

{triangledown} Published ahead of print on 16 July 2008.

{dagger} These authors made equal contributions.

Clinical and Vaccine Immunology, September 2008, p. 1387-1390, Vol. 15, No. 9
1071-412X/08/$08.00+0     doi:10.1128/CVI.00013-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Ochi, H., Kondo, K., Matsumoto, K., Oki, A., Yasugi, T., Furuta, R., Hirai, Y., Yoshikawa, H., Kanda, T. (2008). Neutralizing Antibodies against Human Papillomavirus Types 16, 18, 31, 52, and 58 in Serum Samples from Women in Japan with Low-Grade Cervical Intraepithelial Neoplasia. CVI 15: 1536-1540 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»